Evotec AG AI Stock Analysis
Want to see EVO full AI Analyst Report?
Evotec AG (EVO) AI Stock Analysis
Evotec AG
(NASDAQ:EVO)
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow). Technicals show some near-term stabilization (price above 20/50 DMA and positive MACD) but the longer-term trend remains negative (below 100/200 DMA). The earnings call was constructive with reaffirmed guidance and cost savings progress, but liquidity decline, uneven milestone-driven profitability, and the planned 2027 manufacturing pause temper confidence. Valuation provides limited support due to negative earnings and no dividend.
Evotec AG (EVO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $561.19M
- Dividend Yield
- ―
- Average Volume (3M)
- 106.85K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 1.10
- Revenue Growth
- 0.31%
- EPS Growth
- -19.37%
- Country
- US
- Employees
- 4,553
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Evotec AG Business Overview & Revenue Model
Company Description
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broa...
Evotec AG Earnings Call Summary
The call was predominantly positive. Q3 performance improved materially, D&PD commercial indicators strengthened, Horizon savings were ahead of plan, the Vertex commercial-manufacturing selection advanced JEB, and full-year guidance was reaffirmed with expectations toward the upper end of the ranges. These positives outweighed the weaker nine-month revenue and EBITDA results, lower liquidity, delayed revenue conversion, lower expected Q4 milestones, and the planned 2027 manufacturing pause.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Evotec reaffirmed group revenues of EUR 570 million-EUR 610 million on a reported basis and EUR 595 million-EUR 635 million at constant exchange rates, with adjusted group EBITDA between minus EUR 105 million and minus EUR 70 million, or between minus EUR 90 million and minus EUR 60 million at constant exchange rates; based on current visibility, both revenue and adjusted EBITDA are expected to finish toward the upper end of their respective guidance ranges. Horizon targets approximately EUR 75 million in run rate savings by the end of 2027, with 20%-30% planned for 2026 and more than 20% already delivered by the end of September. By 2030, Evotec’s ambition is around EUR 1 billion in group revenues, with an adjusted EBITDA margin of 20% by the end of 2028 and above 20% by the end of 2030; the framework comprises around 40% D&PD base business, another 20% D&PD strategic partnerships, and approximately 40% JEB, with D&PD base revenues expected to reach approximately EUR 400 million at a CAGR of around 10%, strategic partnerships approximately EUR 200 million at a CAGR of around 5%, and JEB approximately EUR 400 million at a CAGR of around 20%.
Evotec AG Financial Statement Overview
Summary
Despite +14.4% TTM revenue growth and an improved gross margin (13.2% vs 8.3% in 2025), profitability and cash generation are weak: EBIT margin is -14.0%, net margin is -25.2%, and both operating cash flow (~-95M) and free cash flow (~-131M) are negative. The balance sheet is only moderately supportive (debt-to-equity ~0.65), but losses and negative ROE (~-26%) reduce financial flexibility.
Income Statement
28NegativeBalance Sheet
58NeutralCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 720.90M | 757.26M | 796.97M | 781.43M | 751.45M | 618.03M |
| Gross Profit | 94.32M | 62.66M | 114.88M | 175.05M | 174.06M | 151.54M |
| EBITDA | -85.84M | -13.89M | -80.66M | 24.13M | -57.61M | 316.63M |
| Net Income | -183.62M | -99.43M | -196.08M | -83.91M | -175.66M | 215.51M |
Balance Sheet | ||||||
| Total Assets | 1.50B | 1.78B | 1.91B | 2.25B | 2.26B | 2.24B |
| Cash, Cash Equivalents and Short-Term Investments | 418.48M | 476.19M | 396.80M | 604.11M | 707.31M | 858.50M |
| Total Debt | 0 | 447.50M | 443.54M | 815.35M | 506.67M | 512.92M |
| Total Liabilities | 863.31M | 964.64M | 959.98M | 1.13B | 1.07B | 857.48M |
| Stockholders Equity | 641.66M | 813.36M | 952.52M | 1.12B | 1.19B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | -131.32M | -78.74M | -114.02M | -179.56M | 24.46M | 3.29M |
| Operating Cash Flow | -95.29M | -9.06M | 18.22M | 36.44M | 205.81M | 122.24M |
| Investing Cash Flow | 224.14M | 159.86M | -71.19M | -13.29M | -412.80M | -243.85M |
| Financing Cash Flow | -16.76M | -30.93M | -161.42M | 71.96M | -58.15M | 398.43M |
Evotec AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVO, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.60, and below the 200-day MA of 2.42, indicating a bearish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 47.81 is Neutral, neither overbought nor oversold. The STOCH value of 42.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVO.
Evotec AG Risk Analysis
Evotec AG disclosed 10 risk factors in its most recent earnings report. Evotec AG reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEvotec AG Peers Comparison
Overall Rating
RDY68Neutral
ALKS67Neutral
TKNO56Neutral
LFCR50Neutral
EVO50Neutral
HCM49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $12.18B | 41.07 | 7.37% | 0.57% | -10.52% | -55.45% | |
| 67Neutral | $7.90B | 15676.67 | -0.02% | ― | 15.27% | -100.08% | |
| 56Neutral | $516.43M | -27.83 | -24.95% | ― | 15.45% | 12.64% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $243.36M | -3.40 | 381.59% | ― | ― | ― | |
| 50Neutral | $580.81M | -2.91 | -25.63% | ― | 0.31% | -19.37% | |
| 49Neutral | $2.59B | 160.41 | 1.43% | ― | -8.81% | -96.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EVO | Evotec Ag (Adr) | 1.56 | -1.40 | -47.30% | |
| ALKS | Alkermes plc | 46.53 | 17.27 | 59.02% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.70 | 0.76 | 5.43% | |
| LFCR | Lifecore Biomedical, Inc. | 6.42 | -1.18 | -15.59% | |
| HCM | Hutchmed (China) Limited | 14.73 | 0.07 | 0.48% | |
| TKNO | Alpha Teknova, Inc. | 7.77 | 3.36 | 76.19% |
Evotec AG Corporate Events
Evotec Reports Nine-Month 2026 Results, Highlights Transformation and Pipeline Progress
Evotec SE is a drug-discovery and development company providing research, development and biologics manufacturing services, with a market focus on pharmaceutical and biotechnology partners in areas including immunology, oncology and infectious diseas...
Evotec Names Joanna Holbrook Chief Scientific Officer as Investor Holdings Shift
On October 15, 2026, Evotec SE announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board, effective November 1, 2026. Holbrook, a seasoned R&D leader with more than 25 years of experience across p...
Evotec SE Nine-Month 2026 Results Beat Expectations as Full-Year Guidance Reaffirmed
Evotec SE, a Hamburg-based biopharmaceutical drug discovery and development specialist, reported preliminary unaudited figures for the first nine months of 2026 that outperformed market expectations. The company derives its revenues from partnering w...
Evotec SE Announces Chief Scientific Officer Transition as Long-Serving CSO Steps Down
Evotec SE, a Hamburg-based life science company listed on Nasdaq and Frankfurt, specialises in AI-enhanced drug discovery and development across small molecules, biologics and cell therapies. With proprietary technology platforms and a network that i...
Evotec’s Just – Evotec Biologics Starts Phase 1 Trial of Orthopoxvirus Antibodies for U.S. Biodefense
Evotec SE announced on September 9, 2026, that its CDMO subsidiary Just – Evotec Biologics has initiated a first-in-human Phase 1 clinical trial of JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, under the U.S. Department of War’s...
Evotec SE Posts Weaker Half-Year 2026 Results but Presses Ahead With ‘Horizon’ Transformation and Biologics Push
On 13 August 2026, Evotec SE released its half-year 2026 interim report, showing that group revenues fell 19.2% year-on-year to €300.1 million and adjusted EBITDA deteriorated to a loss of €42.7 million amid weak conversion of sales to revenue and ch...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
